Clinical Remission is an Achievable Goal for Patients With Severe Asthma Receiving Mepolizumab in Europe: A Chart Review
Bibliographic record
Abstract
Abstract Rationale: Clinical remission (CR) is an emerging treatment goal for patients with severe asthma. To our knowledge, no real-world studies have a priori evaluated CR while on mepolizumab treatment. This study characterizes patients attaining CR within usual clinical practice in Europe. Methods: A retrospective chart review of adults with severe asthma who initiated mepolizumab was performed by specialists in France, Germany, and Italy. Data were collected 12 months before (baseline) and after mepolizumab initiation (follow-up). CR definition: oral corticosteroid (OCS) freedom, lung function (LF) stabilized (change from baseline in forced expiratory volume percent predicted ≥0%), symptom control (Asthma Control Test [ACT] ≥20), and no asthma exacerbations over follow-up. Results: Patients were abstracted by 85 pulmonologists and 32 allergists. Of 308 patients included (49% male, mean age at treatment initiation [standard deviation, SD] of 43.2 [12.5] years), 267 patients had LF data during baseline and follow-up. Patients had a mean (SD) of 2.2 (1.9) exacerbations in the year prior mepolizumab initiation. At baseline, 92% of patients with available data (81%) had an ACT<20. During the 1-year treatment with mepolizumab, 67% and 79% of the 267 patients remained exacerbation and OCS free, respectively. 65% achieved an ACT≥20, and 89% demonstrated LF stabilization. Overall, 38% (101/267) of patients achieved CR. Conclusions: CR is an ambitious and achievable treatment goal for patients with severe asthma. Real-world results in this European cohort demonstrate consistency with post hoc analyses of observational studies and prior clinical trials. Funding: GSK (219507).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.009 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.003 | 0.004 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".